[{"orgOrder":0,"company":"Boundless Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"ecDNA","graph1":"Oncology","graph2":"Discovery","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Boundless Bio \/ Nextech Invest"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBI-825","moa":"RNR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Leaps by Bayer"}]